Naftidrofuryl for intermittent claudication: Meta-analysis based on individual patient data

BMJ (Online)

Volumn 338, Issue 7696, 2009, Pages

  De Backer, T ^a,b   Stiehele, R Vander ^a   Lehert, P ^c   Van Bortel, L ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Facultes Universitaires Catholiques de Mons   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

NAFTIDROFURYL; PLACEBO;

ANALGESIA; ARTICLE; CALCIUM OXALATE STONE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG EFFICACY; HEART ARRHYTHMIA; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INTERMITTENT CLAUDICATION; LIVER INJURY; META ANALYSIS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SKIN MANIFESTATION; STOMACH DISEASE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WALKING;

FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; NAFRONYL; PAIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASODILATOR AGENTS; WALKING;

EID: 84859002490     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b603     Document Type: Article

References (61)

1. Hiatt WR, Hoag S, Hamman RF. Effect of diagnostic criteria on the prevalence of peripheral arterial disease. The San Luis Valley Diabetes Study. Circulation 1995;91:1472-9.
2. Fowkes FG, Housley E, Cawood EH, Macintyre CC, Ruckley CV, Prescott RJ. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int 1 Epidemiol 1991;20:384-92.
3. Sprynger M, Fassotte C, Verhaeghe R. The ankle-brachial pressure index and a standardized questionnaire are easy and useful tools to detect peripheral arterial disease in non-claudicating patientsat high risk. IntAngiol 2007;26:239-44.
4. Sigvant B, Wiberg-Hedman K, Bergqvist D, Rolandsson 0, Andersson B, Persson E, et al. A population-based study of peripheral arterial disease prevalence with special focus on critical limb ischemia and sex differences. J Vase Surg 2007;45:1185-91.
5. Dormandy (A, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vase Surg 2000;31:51-296.
6. Carman TL, Fernandez BB, Jr. A primary care approach to the patient with claudication. Am Earn Phys 2000;61:1027-32,1034.
7. Li XY, Wang |, He Y, Fan L. The relation between peripheral arterial occlusive disease and cardiovascular diseases in elderly population: a cross-section study in Wanshoulu area, Beijing. ZhonghuaYiXueZa Zhi 2003;83:1847-51.
8. Robbs JV. Atherosclerotic peripheral arterial disease in blacks-an established problem. SAfr Med J 1985;67:797-801.
9. Madiba TE, Mars M, Robbs JV. Aorto-iliac occlusive disease in the various population groups of South Africa. SAfr Med J 2001;91:785-6.
10. Coffman JD. Drug therapy: vasodilator drugs in peripheral vascular disease. N Engl J Med 1979;300:713-7.
11. Criqui MH, Coughlin SS, Fronek A. Noninvasively diagnosed peripheral arterial disease as a predictor of mortality: results from a prospective study. Circulation 1985;72:768-73.
12. Hooi JD.KesterAD, Staffers HE, RinkensPE, Knottnerus JA, van Ree JW. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol 2004;57:294-300.
13. Verhaeghe R. Epidemiology and prognosis of peripheral obliterative arteriopathy. Drugs 1998;56(suppl 3):1-10.
14. Selvin E, ErlingerTP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004;110:738-43.
15. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000;(2):CD00099Q.
16. Mohler ER, III, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003;108:1481-6.
17. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease ofthe lower limb. Cochrane Database Syst Rev2007;(4):CD000123.
18. Clement DUDebuyzere ML. How to treat hypertension in patients with peripheral artery disease. CurrHypertens Rep 2007;9:190-5.
19. Catalano M, Born G, Peto R. Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 2007;261:276-84.
20. Annemans L, Lamotte M, Clarys P, Van den Abeele E. Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases. Eur I CardiovascPrevRehabil2007;U:815-24.
21. Lee HL, Mehta T, Ray B, Heng MS, McCollum PT, ChetterlC. A non- randomised controlled trial ofthe clinical and cost effectiveness of a supervised exercise programme for claudication. Eur I Vase Endovasc Surg 2007;33:202-7.
22. Hankey GJ, Norman PE, Eikelboom JW. Medical treatment of peripheral arterial disease. JAMA 2006;295:547-53.
23. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995;274:975-80.
24. Gardner AW, Katzel LI, Sorkin |D, Killewich LA, Ryan A, Flinn WR, et al. Improved functional outcomes following exercise rehabilitation in patients with intermittent claudication. J Gerontol A Biol Sci Med Sci 2000;55:M570-7.
25. Gardner AW, Katzel LI, Sorkin JD, Bradham DD, Hochberg MC, Flinn WR, et al. Exercise rehabilitation improves functional outcomes and peripheral circulation in patients with intermittent claudication: a randomized controlled trial. J Am GeriatrSoc 2001;49:755-62.
26. Gartenmann C, Kirchbergerl, HerzigM, Baumgartnerl, Saner H, Mahler F, et al. Effects of exercise training program on functional capacity and quality of life in patients with peripheral arterial occlusive disease. Evaluation of a pilot project. Vasa 2002;31:29-34.
27. Christman SK, Ahijevych K, Buckworth J. Exercise training and smoking cessation as the cornerstones of managing claudication. J Cardiovasc Nurs 2001;15:64-77.
28. Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev 2007;(1):CD003748.
29. Moher D, Pham B, Ausejo M, Saenz A, Hood S, Barber GG. Pharmacological management of intermittent claudication: a metaanalysis of randomised trials. Drugs 2000;59:1057-70.
30. Girolami B, Bernardi E, Prins MH, Ten Cate JW, Hettiarachchi R, PrandoniP, etal. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a metaanalysis. Arch intern Med 1999;159:337-45.
31. Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: a meta-analysis of randomized controlled trials. OVMJ1996;155:1053-9.
32. Walker GA, Mac Hannaford JC. A meta-analysis of randomized, double-blind, placebo-controlled studies ofthe effect of buflomedil on intermittent claudication. FundamClinPharmacoll995;9:387-94.
33. Lehert P, Riphagen FE, Gamand S. The effect of naftidrofuryl on intermittent claudication: a meta-analysis. J Cardiovasc Pharmacol 1990;16(suppl3):S81-6.
34. De Backer TL, Vander Stichele RH, Warie HH, Bogaert MG. Oral vasoactive medication in intermittent claudication: utileorfutile?Eur J Clin Pharmacol 2000;56:199-206.
35. Barradell LB, Brogden RN. Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease. Drugs Aging 1996;8:299-322.
36. Boobis LH, Bell PR. Can drugs help patients with lower limb ischaemia? Br J Surg 1982;69(suppl):S17-23.
37. Spitzer S, Bach R, Schieffer H. Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review. Int Angiol 1992;11:204-10.
38. Bevan EG, Waller PC, Ramsay LE. Pharmacological approaches to the treatment of intermittent claudication. Drugs Aging 1992;2:125-36.
39. ClementDL.Medical treatment of peripheral artery occlusive disease (PAOD). Acta Chir Belg 2000;100:190-3.
40. Jacoby D, Mohler ER, III. Drug treatment of intermittent claudication. Drugs 2004;64:1657-70.
41. Goldsmith DR, Wellington K. Naftidrofuryl: a review of its use in the treatment of intermittent claudication. Drugs Aging 2005;22:967-77.
42. Heidrich H. Vasoactive agents and prostanoids in the therapy of PAD: facts, questions, disproven assumptions. Hamostaseologie 2006;26:220-3.
43. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Ham's KA, Fowkes FG, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur] Vase Endovasc Surg 2007;33(suppl l):Sl-75.
44. Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral arterial disease. A national clinical guideline. Edinburgh: SIGN, 2006:1-34.
45. Fletcher J. What is heterogeneity and is it important? BMJ 2007;334:94-6.
46. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan D), etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
47. Cameron HA, Waller PC, Ramsay LE. Drug treatment of intermittent claudication: critical analysis of the methods and findings of published clinical trials, 1965-1985. Br J Clin Pharmacol 1988;26:569-76.
48. Committee for Proprietary Medicinal Products Working Party. Note for guidance on clinical investigations of medicinal products in the treatment of chronic peripheral arterial occlusive disease, London: The European Agency for the Evaluation of Medicinal Products, Oct 2002.
49. Anderson TW. Maximum likelihood estimates for a multivariate normal distribution when some observations are missing. J Am Stat Assoc 1957;55:200-3.
50. Simmonds MC, Higgins JP, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials 2005;2:209-17.
51. Higgins IP, Whitehead A, Turner RM, Omar RZ, Thompson SG. Metaanalysis of continuous outcome data from individual patients. Stat Med 2001;20:2219-41.
52. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin mate 1986;7:177-88.
53. Turner RM, Omar RZ, YangM, Goldstein H, Thompson SG. A multilevel model framework for meta-analysis of clinical trials with binary outcomes. Stat Med 2000;19:3417-32.
54. Cholongitas E, Papatheodoridis GV, Mavrogiannaki A, Manesis E. Naftidrofuryl-induced liver injury. Am I Gastroenterol 2003;98:1448-50.
55. HebutemeX, Laugery A, Chichmanian RM.Tran A, Rampal P. Acute cytolytic hepatitis probably caused by naftidrofuryl. Gastroenterol Clin Biol 1990;14:514-5.
56. De Caestecker)S, Heading RC. Naftidrofuryl-induced acute hepatic necrosis. Postgrad Med J 1986;62:309-10.
57. Moesch C, Rince M, Daudon M, Aldigier JC, Leroux-Robert C. Renal intratubular crystallisation of calcium oxalate and naftidrofuryl oxalate. Lancet 1991;338:1219-20.
58. Moesch C, Charmes JP, Bouthier F, Leroux-Robert C. Calcium oxalate crystalluria in elderly patients and treatment with naftidrofuryl oxalate. Age Ageing 1995;24:464-7.
59. Rey JL, MarekA, Tribouilloy C, JarryG, Slama MA, AvineeP, etal. Massive poisoning by naftidrofuryl with severe disorders of rhythm and conduction. Arch Mat Coeur Vaiss 1989;82:1467-71.
60. Muller-Buhl U, EngeserP, Klimm HD, Wiesemann A. Quality of life and objective disease criteria in patients with intermittent claudication in general practice. Fam Pract 2003;20:36-40.
61. Spengel F, Clement D, Boccalon H, Liard F, Brown T, Lehert P. Findings of the naftidrofuryl in quality of life (NIQOL) European study program. IntAngiol 2002;21:20-7.